Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
JANX | US
1.57
3.61%
Healthcare
Biotechnology
30/06/2024
04/10/2024
45.02
44.72
45.48
43.44
Janux Therapeutics Inc. a clinical stage biopharmaceutical company develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen epidermal growth factor receptor and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition its PSMA-TRACTr is designed to target PSMA a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2 a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.0%1 month
59.3%3 months
58.9%6 months
71.7%-
-
3.67
0.04
0.03
-33.80
118.34
-
-63.86M
2.35B
2.35B
-
-155.36
-
741.70
-9.20
6.67
12.53
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
9.69
Range1M
11.00
Range3M
17.72
Rel. volume
0.63
Price X volume
18.58M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
SPRINGWORKS THERAPEUTICS INC. | SWTX | Biotechnology | 32.64 | 2.42B | -0.58% | n/a | 1.27% |
IBRX | IBRX | Biotechnology | 3.43 | 2.39B | -3.92% | n/a | -143.04% |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 40.84 | 2.35B | -2.18% | n/a | 16.11% |
Arrowhead Pharmaceuticals Inc | ARWR | Biotechnology | 18.82 | 2.34B | -2.08% | n/a | 137.39% |
KEROS THERAPEUTICS INC. | KROS | Biotechnology | 60.9 | 2.30B | -0.67% | n/a | 3.32% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -33.80 | 0.76 | Cheaper |
Ent. to Revenue | 118.34 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.67 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 58.88 | 74.67 | Lower Risk |
Debt to Equity | 0.04 | -1.82 | Expensive |
Debt to Assets | 0.03 | 0.26 | Cheaper |
Market Cap | 2.35B | 3.73B | Emerging |